No abstract

Although the head and rod domains of intermediate filament (IF) proteins are known to play significant roles in filament assembly, the role of the tail domain in this function is unclear and the available information supports contradictory conclusions. We examined this question by comparing transfection of the same cDNA constructs, encoding vimentins with modified tail domains, into cell lines that do and do not contain endogenous IF proteins. By this approach, we were able to distinguish between the ability of a mutant IF protein to initiate assembly de novo, from that of incorporating into existing filament networks. Vimentins with modifications at or near a highly conserved tripeptide, arg-asp-gly (RDG), of the tail domain incorporated into existing IF networks in vimentin-expressing (vim+) cells, but were assembly-incompetent in cells that did not express IF proteins (vim-). The failure of the RDG mutant vimentins to assemble into filament arrays in vim- cells was reversible by re-introducing a wild-type vimentin cDNA, whereupon both wild-type and mutant vimentins coassembled into one and the same IF network. We conclude that the function of the tail domain of type III IF proteins, and possibly of keratins K8 and K18, in IF assembly is distinct from those of other domains; a region encompassing the RDG tripeptide appears to be important in the assembly process.

ФГБОУ ВО «Волгоградский государственный медицинский университет»Министерства здравоохранения Российской Федерации, кафедра инфекционных болезней с эпидемиологией и тропической медициной В статье представлены данные об особенностях клиники и сдвигов в иммунологическом статусе у больных ВИЧ/ СПИД с саркомой Капоши, принимающих антиретровирусную терапию, а также факторы, определяющие прогноз течения болезни.

The purpose of the research is developing tools for forecasting changes in the service system during the period when new models of automotive vehicles are being introduced to the market. Research objectives: development of the structure and composition of decision support systems to improve the competitiveness of the service system, development of a mathematical model of a dealer-service network and a simulation model of the network of the Republic of Kazakhstan. The simulation model takes into account the following parameters: the percentage of satisfaction for applications for spare parts directly from the warehouse, the number of posts, the number of workers, the distribution of the flow of applications from the concentration of vehicles in the service center, the mode of operation of the service center. The following research methods were used: methods of system analysis and mathematical statistics, elements of the theory of reliability, simulation, computer experiment. After verification and validation of the developed model, a computer experiment was conducted with the current parameters. The obtained simulation values are reliable at a 5% significance level. The following result was achieved: a simulation model was built for the functioning of the dealer-service network that can be used in strategic planning for expanding the service network and entering new markets.

Background. Even the mild course of atopic dermatitis (AD) requires the complex approach to the exacerbation therapy and prevention. Systematic skin care is the cornerstone of AD antirelapse therapy, but the emollients price might interfere the compliance. The study aim was to evaluate clinical effectiveness and pharmacoeconomics of therapeutic skin care complex Atopic (daily cream, reliver cream and shower gel) in children with AtD. Materials and methods. Open prospective evaluation of 1-month long. There were 50 children (6 month to 18 years old) with AtD included in 2 groups (exacerbation and remission, 25 children each). We have evaluated mean values of SCORAD index, skin itching and dryness (visual analog scales), pharmacotherapy requests and number of AtD exacerbations. Emollients’ consumption was determined by used packs’ weighting. Month total emollients’ outlay and 1 remission day cost with the Atopic therapeutic skin care complex application were calculated. Results. 47 patients (94%) had completed the protocol; 3 children had stopped Atopic applications due to individual intolerance. After 1 month in AtD exacerbation group mean SCORAD-index score had decreased from 41,8±4,6 to 13,4±2,7 (р=0,0001); in remission group initially low SCORAD results (7,2±0,9) hadn’t changed (6,3±1,8). Among outlay subgroups the daily cream cost was predominant. Mean 1 remission day cost was 72.9 and 52.4 rubles/day for groups 1 and 2, respectively. Conclusions. Gathered data allow to characterize Atopic complex as attractive quality/price ratio cosmetics and to recommend their wide usage in long-term anti-relapse AtD therapy in children.